HOME >> MEDICINE >> NEWS
Lithium may protect neurons from radiation therapy

NASHVILLE, Tenn. (Oct. 8, 2004) -- Patients who undergo radiation for treatment of brain tumors may survive their cancer only to have lasting memory and learning deficiencies, the impact of which can be particularly devastating for children.

Now, researchers at the Vanderbilt-Ingram Cancer Center have discovered that lithium, a drug commonly used to treat bipolar disorder and other mental illnesses, can protect the brain cells involved in learning and memory from radiation damage.

While the work has been conducted in cell culture and animal studies thus far, clinical trials are expected to be conducted soon to test whether the drug can protect humans from cognitive deficits as a result of cranial radiation therapy.

The researchers presented their work during the 46th annual meeting of the American Society for Therapeutic Radiology and Oncology, earlier this week in Atlanta.

"In addition to killing cancer cells, radiation can cause cell death apoptosis in normal cells as well," said Dennis Hallahan, M.D., professor and chair of Radiation Oncology at Vanderbilt University School of Medicine in Nashville, Tenn. "Particularly susceptible are neurons in the hippocampus, the part of the brain that plays a crucial role in learning and memory."

Lithium is an inhibitor of a protein that causes apoptosis called glycogen synthase kinase 3 b. Studies suggest that it may protect neurons from a variety of cytotoxic insults, including observations that the incidence of Alzheimer's disease which leads to progressive and profound memory loss is lower among patients who take lithium for mental illness, Hallahan said.

The researchers observed in animal models that a single radiation dose of 5 Gy caused a massive amount of apoptosis in the hippocampus but not in other areas of the brain.

However, treatment of a mouse hippocampus cell with lithium for a week prior to 3 Gy of radiation resulted in a 60 percent increase in cell survival; a week'
'"/>

Contact: Cynthia Floyd Manley
cynthia.manley@vanderbilt.edu
615-936-5711
Vanderbilt University Medical Center
8-Oct-2004


Page: 1 2

Related medicine news :

1. Conference Celebrates Lithiums 50 Years As A Miracle Drug
2. UK Allied Health Professor Receives Patent On Using Lithium With AIDS Drugs
3. Research Explains Lithiums Dual Anti-Manic/Anti-Depressive Effect
4. New study in Nature demonstrates protection against cell death during heart attack
5. Simple intervention encourages sun protection behaviors
6. Red wine protects the heart
7. Sunflower seed oil can protect low birth weight babies from infection
8. Physical activity linked to protection from Parkinsons disease
9. Component of green tea protects injured livers in mice
10. Study shows protective equipment not very effective for rugby players
11. Least protection offered to those most at risk of sudden cardiac death

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Lithium may protect neurons from radiation therapy

(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: